Overview

Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

Status:
Completed
Trial end date:
2018-07-11
Target enrollment:
Participant gender:
Summary
This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche
Ignyta, Inc.
Treatments:
Entrectinib
Midazolam